您的位置：山东大学 -> 科技期刊社 -> 《山东大学学报（医学版）》

山东大学学报（医学版） ›› 2016, Vol. 54 ›› Issue (9): 77-81.doi: 10.6040/j.issn.1671-7554.0.2016.005

• • 上一篇    下一篇

不同时期抗病毒治疗对艾滋病患者耐药产生的影响分析

袁源1,司珩1,刘宏伟1,刘春华1,王哲1,阮玉华2,邢辉2   

  1. 1.河南省疾病预防控制中心性病艾滋病防治研究所, 河南 郑州 450016;2.中国疾病预防控制中心性病艾滋病预防控制中心, 北京102206
  • 收稿日期:2016-01-04 出版日期:2016-09-10 发布日期:2016-09-10
  • 通讯作者: 刘宏伟. E-mail:Hongweiliu36@163.com E-mail:Hongweiliu36@163.com
  • 基金资助:
    河南省重点科技攻关计划(102102310003、112102310005)

HIV drug resistance and the impact of antiretroviral therapy initiated at different stages among AIDS patiens

YUAN Yuan1, SI Heng1, LIU Hongwei1, LIU Chunhua1, WANG Zhe1, RUAN Yuhua2, XING Hui2   

  1. 1. Institute for AIDS/STD Prevention and Cure, Henan Center for Disease Control and Prevention, Zhengzhou 450016, Hennan, China;
    2. National Center for AIDS/STD Control and Prevention, China CDC, Beijing 102206, China
  • Received:2016-01-04 Online:2016-09-10 Published:2016-09-10

PDF (PC)

882

摘要： 目的 比较不同时机开始抗病毒治疗对艾滋病患者耐药产生的影响。 方法 对河南省接受一线抗病毒治疗方案>6个月的艾滋病患者进行横断面调查,根据基线免疫水平,将调查对象分为早期治疗组(CD4+T淋巴细胞≥350个/mm3)132例、常规治疗组(CD4+T淋巴细胞201个/mm3~349个/mm3)200例和延迟治疗组(CD4+T淋巴细胞≤200 个/mm3)329例。通过多因素Logistic回归,分析抗病毒治疗患者耐药发生的影响因素。 结果 共调查符合条件的抗病毒治疗患者661例,总耐药率为34.3%(227/661),其中早期治疗组、常规治疗组和延迟治疗组出现耐药突变的比例分别为21.2%(28/132)、 35.5%(71/200)和 38.9%(128/329)。多因素Logistic回归分析显示,早期治疗(OR=0.31, 95%CI 0.19~0.51, P<0.001)、依从性高(OR=0.48, 95%CI 0.30~0.78, P=0.003)和含3TC初始治疗方案(OR=0.20, 95%CI 0.20~0.40, P<0.001)是影响抗病毒治疗耐药产生的保护因素,治疗时间长(OR=1.90, 95%CI 1.22~2.95, P=0.004 3)是影响抗病毒治疗耐药产生的危险因素。 结论 早期开始抗病毒治疗可减少抗病毒治疗患者耐药毒株的产生,能取得良好的抗病毒治疗效果。

关键词: 影响因素, 艾滋病, 早期抗病毒治疗, 耐药

Abstract: Objective To compare the impact of antiretroviral therapy initiated at different stages on drug resistance among AIDS patients. Methods AIDS patients treated with first-line HAART for 6 months in Henan Province were investigated with cross-sectional survey and blood samples were collected. According to the level of baseline immunology, the patients were divided into 3 groups: early treatment group(n=132, CD4+T cell counts ≥ 350 cell/mm3), conventional treatment group(n=200, 200 cell/mm3 < CD4+T cell counts < 350 cell/mm3)and delayed treatment group(n=329, CD4+T cell counts ≤ 200 cell/mm3). The factors associated with the development of HIV-1 drug resistance were analyzed with multivariate logistic regression. Results A total of 661 patients were investigated. The total prevalence of HIV-1 drug resistance was 34.3%(227/661). The prevalence of drug resistance in the early treatment group, conventional treatment group and delayed treatment group was 21.2%(28/132), 35.5%(71/200)and 38.9%(128/329), respectively. Multivariate logistic regression analysis showed that the protective factors associated with the development of drug resistance included earlier treatment(OR=0.31, 95%CI 0.19-0.51, P<0.001), high compliance(OR=0.48, 95%CI 0.30-0.78, P=0.003)and initiation of ART with 3TC(OR=0.20, 95%CI 0.20- 山 东 大 学 学 报 (医 学 版)54卷9期 -袁源,等.不同时期抗病毒治疗对艾滋病患者耐药产生的影响分析 \=-0.40, P<0.001), while long-duration of treatment(OR=1.90, 95%CI 1.22-2.95, P=0.004 3)was the risk factor. Conclusion Early initiation of antiretroviral therapy for AIDS patients receiving HAART could reduce the emergence of the drug resistant strains and acquire good effect.

Key words: Acquired Immune Deficiency Syndrome, Early initiation of antiretroviral therapy, Influencing factor, Drug resistance

中图分类号: 

  • R183.9
[1] Mwesigire DM, Wu AW, Martin F, et al. Quality of life in patients treated with first-line antiretroviral therapy containing nevirapine or efavirenz in Uganda: a prospective non-randomized study[J]. BMC Health Serv Res, 2015,15: 292. doi: 10.1186/s12913-015-0959-0.
[2] Hong SY, Jonas A, DeKlerk M, et al. Population-based surveillance of HIV drug resistance emerging on treatment and associated factors at sentinel antiretroviral therapy sites in Namibia[J]. J Acquir Immune Defic Syndr, 2015, 68(4): 463-471.
[3] Hosseinipour MC, Gupta RK, Van Zyl G, et al. Emergence of HIV drug resistance during first- and second-line antiretroviral therapy in resource-limited settings[J]. J Infect Dis, 2013, 207(Suppl 2): S49-56.
[4] Wang J, Wang Z, Liao L, et al. Efficacy and HIV drug resistance profile of second-line ART among patients having received long-term first-line regimens in rural China[J]. Sci Rep, 2015, 5: 14823. doi: 10.1038/srep14823.
[5] Liao L, Xing H, Su B, et al. Impact of HIV drug resistance on virologic and immunologic failure and mortality in a cohort of patients on antiretroviral therapy in China[J]. AIDS, 2013, 27(11): 1815-1824.
[6] Xing H, Ruan Y, Li J, et al. HIV drug resistance and its impact on antiretroviral therapy in Chinese HIV-infected patients[J]. PLoS One, 2013, 8(2): e54917. doi: 10.1371/journal.pone.0054917. Epub 2013 Feb 6.
[7] Kaleebu P, Kirungi W, Watera C. Virological response and antiretroviral drug resistance emerging during antiretroviral therapy at three treatment centers in uganda[J]. PLoS One, 2015, 10(12): e0145536. doi: 10.1371/journal.pone.0145536. eCollection 2015.
[8] 孙定勇, 王奇, 杨文杰, 等. 河南省2003-2009年艾滋病抗病毒治疗患者生存状况分析[J]. 中华流行病学杂志, 2012, 33(2): 181-184. SUN Dingyong, WANG Qi, YANG Wenjie, et al. Survival analysis on AIDS antiretroviral therapy in Henan province during 2003-2009[J]. Chinese Journal of Epidemiology, 2012, 33(2): 181-184.
[9] 杨文杰, 樊盼英, 梁妍, 等. 2008-2013年河南省艾滋病患者抗病毒治疗对HIV的抑制效果及其影响因素分析[J]. 中华预防医学杂志, 2015, 49(1): 13-20. YANG Wenjie, FAN Panying, LIANG Yan, et al. Analysis on HIV suppression effect after initiating antiretroviral treatment and related factors among AIDS patients in Henan province during 2008 and 2013[J]. Chinese Journal of Preventive Medicine, 2015, 49(1): 13-20.
[10] 中国疾病预防控制中心. 国家免费艾滋病抗病毒治疗手册[M]. 3版.北京: 人民卫生出版社, 2012.
[11] Jiamsakul A, Sungkanuparph S, Law M, et al. HIV multi-drug resistance at first-line antiretroviral failure and subsequent virological response in Asia[J]. J Int AIDS Soc, 2014, 17: 19053. doi: 10.7448/IAS.17.1.19053. eCollection 2014.
[12] 崔卫国, 薛秀娟, 刘佳, 等. 河南省沈丘县抗病毒治疗者HIV耐药株流行状况调查[J]. 中华流行病学杂志, 2013, 34(3): 218-220. CUi Weiguo, XUE Xiujuan, LIU Jia, et al. A cross-sectional study on the prevalence of HIV drug resistance in patients receiving antiretroviral treatment in Shenqiu county, Henan province[J]. Chinese Journal of Epidemiology, 2013, 34(3): 218-220.
[13] Jain V, Byonanebye DM, Amanyire G, et al. Successful antiretroviral therapy delivery and retention in care among asymptomatic individuals with high CD4+ T-cell counts above 350 cells/μl in rural Uganda[J]. AIDS, 2014, 28(15): 2241-2249.
[14] Wang J, He C, Hsi JH, et al. Virological outcomes and drug resistance in Chinese patients after 12 months of 3TC-based first-line antiretroviral treatment, 2011-2012[J]. PLoS One, 2014, 9(2): e88305. doi: 10.1371/journal.pone.0088305. eCollection 2014.
[15] 丁佩佩, 何纲, 陈晓华, 等. 不同CD4+细胞水平HIV感染者抗病毒治疗的疗效及药物不良反应分析[J].中国医师杂志, 2015, 17(1): 52-57. DING Peipei, HE Gang, CHEN Xiaohua, et al. Efficacy and side effects of HAART in HIV-infected patients with different CD4 cell counts[J]. Journal of Chinese Physician, 2015, 17(1): 52-57.
[16] Xing H, Ruan Y, Hsi JH, et al. Reductions in virological failure and drug resistance in Chinese antiretroviral-treated patients due to lamivudine-based regimens, 2003-12[J]. J Antimicrob Chemother, 2015, 70(7): 2097-2103.
[1] 葛丽娟 金瑞峰 王纪文 许新升 李癊. 多药耐药基因1 C1236T多态性与癫痫患者对药物反应性的相关性[J]. 山东大学学报(医学版), 2209, 47(6): 99-102.
[2] 林明霞,刘桂斌,马燕花,连曌昱,任洋洋. ATP酶铜转运蛋白α介导的铜死亡途径及在肿瘤治疗中的价值[J]. 山东大学学报 (医学版), 2026, 64(4): 117-124.
[3] 孙佳丽,王亮,王长凤,张杰,郭磊. Klippel-Trenaunay综合征儿童情绪与行为特征及其影响因素[J]. 山东大学学报 (医学版), 2026, 64(3): 78-82.
[4] 宋一鸣,王佳丰,韩晓娟,杜怡峰. 脑维持与认知功能:测量、影响因素和机制[J]. 山东大学学报 (医学版), 2026, 64(1): 1-7.
[5] 徐欣颖,颜伟,石兴龙,岳芳,吕婧,乔颖异,张宇琦,程传龙,左慧,李秀君. 山东省滨州市手足口病的流行特征及影响因素[J]. 山东大学学报 (医学版), 2026, 64(1): 118-125.
[6] 孙爽爽,仉率杰,张伯韬,袁莹,于媛媛,薛付忠. 基于真实世界研究的18~50岁人群急性缺血性卒中影响因素[J]. 山东大学学报 (医学版), 2025, 63(9): 40-46.
[7] 王宁,郝秀梅,牛翔,黄金明,徐静雅. 中国中老年高血糖、血脂异常、高血压人群健康体检服务利用现状及影响因素[J]. 山东大学学报 (医学版), 2025, 63(7): 82-91.
[8] 王莹,李怀臣,龙飞,刘铱. 基于三种统计模型的长期空气污染物混合暴露与耐药性结核病发病风险关联[J]. 山东大学学报 (医学版), 2025, 63(7): 92-101.
[9] 张永媛,王清亮,连雪洪. 山东省某三级综合医院罕见病患者住院费用结构变动情况及影响因素[J]. 山东大学学报 (医学版), 2025, 63(5): 111-119.
[10] 陈瑛翼,游倩,王意,张帆,李凤,季舒铭,徐浩源,饶志勇. 办公室职员肌肉质量减少预测模型的开发与验证[J]. 山东大学学报 (医学版), 2025, 63(4): 26-35.
[11] 刘国伟,翟艳,王薇,吕军城. 潍坊市某城区65岁及以上老年人社会适应能力现状及其影响因素[J]. 山东大学学报 (医学版), 2025, 63(2): 104-110.
[12] 穆弘杰,卢伟,吕军城. 居民抑郁、焦虑症状和心理健康素养现况及影响因素分析[J]. 山东大学学报 (医学版), 2025, 63(12): 105-111.
[13] 宋雅雯,郭联涛,孔德光,孙圣荣. VTCN1导致HR+乳腺癌预后不良及内分泌治疗耐药[J]. 山东大学学报 (医学版), 2025, 63(1): 43-59.
[14] 刘峰,马彩霞,李春燕,程海英,靳乐雨,刘仲,李学文. 2023年11月流感高峰期济南市大学生流感样病例发生情况及影响因素[J]. 山东大学学报 (医学版), 2024, 62(7): 91-97.
[15] 刘超,刁婷婷,张红吉,刘红伟,杨永锐,李晓非. 飞行时间质谱在耐药结核病检测中的应用价值[J]. 山东大学学报 (医学版), 2024, 62(4): 61-67.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
No Suggested Reading articles found!
版权所有 © 2018 《山东大学学报(医学版)》编辑部　
地址:山东大学科技期刊社（济南市历城区山大南路27号山东大学中心校区明德楼B座721室） 电话: 0531-88366918 E-mail: xbyxb@sdu.edu.cn
本系统由北京玛格泰克科技发展有限公司设计开发